Lipid profile in children of β-thalassemia major and their correlation with serum ferritin

Rameshwar L. Suman, Anuradha Sanadhya, Pradeep Meena, Jaskaran Singh, Rupali Jain, Suresh Meena


Background: β-thalassemia major is a secondary iron load state. The high serum ferritin accounts for abnormal lipid profile. This study was done to investigate the lipid profile in children with β-thalassemia major and to know their correlation with serum ferritin.

Methods: Fifty-five (55) children of beta thalassemia major in the age group of 4-20 years from thalassemia unit of tertiary care hospital who were on regular blood transfusion and oral iron chelators were enrolled. Serum ferritin levels and lipid profile of these children were investigated and their correlation was assessed.

Results: Out of total 55 children 31 (56.4%) children were of female sex and 48(87.3%) were Hindu by religion. The mean rate of blood transfusion was 157.02±21.33 ml/kg/year with average dose and duration of iron chelation with Desferroxamine was 34.4±26.86 mg/kg /day and 2.34±1.86 years respectively. Mean cholesterol level, high density lipoprotein (HDL), low density lipoprotein (LDL) levels were on lower side of the range with values of 124.47±19.81 mg/dl, 36.58±12.22 mg/dl, 63.94±4.57 mg/dl respectively. The mean triglyceride level (TG) was on higher side with an average of 142.93±33.7 mg/dl. The average serum ferritin levels were 2130.33±859.85 ng/ml. There was negative correlation of total cholesterol, HDL, LDL with serum ferritin with coefficient of correlation (r= -0.77, -0.55, -0.72) respectively. The serum triglyceride had positive correlation with serum ferritin with coefficient of correlation(r=+0.85).

Conclusions: As the serum ferritin increases, there occurs more derangement of lipid profile in form of decreasing serum cholesterol, HDL, LDL and increasing serum TG levels.


Dyslipidemia, Hemoglobinopathy, Serum Ferritin, Thalassemia

Full Text:



Michel RD, Melissa JF. Elliott. Thalassemia syndrome. In Kleigman RM, Stanton BF, St Geme JW, Behrman RE. Nelson’s textbook of Paediatrics.17th edition. Elsevier publication. 2012;2397-2414.

Verma IC, Choudhary VP, Jain PK. Prevention of thalassemia. a necessity in India. Indian J Paediatr. 1992;59:649-54.

Richa J, Sachdeva A. Iron overload and its manifestations. In Sachdeva A, Jain R, Aggarwal RK, Yadav SP, Broker A. Manual of thalassemia IAP, Pediatric Hemato Oncology. 2009;76-115.

Goldfarb A, Rachmilewitz A, Elsemberg S. Abnormal low and high density lipoproteins in homozygous β thalassemia an Italian multicentric stydy. Acta Hematol. 1998;99:76-9.

Hillenbra CMR, Loeffler B, Carville M. Evaluation on hepatic iron concentration by T2 MRI in patients with iron overload. Proc Intl Soc Mag Reson Med. 2005;105:855-61.

Liverea MA, Tesoriere L, Pintaudi AM. Oxidative stress and antioxidant status in beta thalassemia major. Iron overload and depletion of lipid soluble antioxidents. Blood. 1996;88(9):3608-14.

Scott MD, Eaton JW. Thalassemic erythrocytes. Cellular suicide arising from iron and glutathione dependent oxidation reaction. Br J Haematol. 1995;91:811-9.

Papanastasiou. Expert panel on detection, evealuation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-97.

Kaltwassen JP, Gottschalk. Erythropoietin and iron. Kidney International Supplements. 1999;69:49-56.

Mansi KM, Aburjaf TA. Lipid profile in Jordian children with β thalassemia major. UHOD. 2008;18(2);93-8.

Louis CK. Low growth. Growth of children with thalassemia major. Indian J Paediatr. 2005;72;159-64.

Patne AB, Hisalkar PJ, Gaikwad SB. Lipid abnormalities in patients with beta thalassemia major. Int J Pharma Sci. 2012;2(1):106-12.

Adlette I, Mohammadhassan A, Noureldine, Mansour A, Abbas HA. Endocrine and bone complications in beta-thalassemia intermedia: current understanding and treatment. Bio Med Res Int. 2015;10:1155.